Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Publication year range
1.
Allergy Asthma Clin Immunol ; 19(1): 83, 2023 Sep 09.
Article in English | MEDLINE | ID: mdl-37689703

ABSTRACT

BACKGROUND: To investigate the role of combined impulse oscillometry (IOS) and fractional exhaled nitric oxide (FeNO) in the diagnosis of cough variant asthma (CVA) in preschool children. METHODS: A total of 197 preschool-aged children with chronic cough were selected from the paediatric outpatient clinic. Allergy histories were collected for all children along with IOS and FeNO. Paediatric respiratory specialists divided the children into a CVA group (n = 90) and a noncough variant asthma (nCVA) group (n = 107) according to the diagnostic criteria for CVA After diagnostic treatment, the correlation between the FeNO and IOS values and the diagnosis in the two groups was analysed, and the area under the curve (AUC) of each index was calculated. RESULTS: (1) X5 was significantly different between the CVA group and the nCVA group (- 4.22 vs. - 3.64, p < 0.001), as was the FeNO value (29.07 vs. 16.64, p < 0.001). (2) Receiver operating characteristic (ROC) analysis showed that the AUCs of FeNO alone and X5 alone were 0.779 and 0.657, respectively, while the AUC of FeNO (cut-off value of 18 ppb) plus X5 (cut-off value of -4.15 cmH2O/(l/s)) reached 0.809. CONCLUSIONS: Children with CVA may have small airway dysfunction at an early stage. For preschool children with chronic cough, the combination of FeNO and X5 can better identify those with CVA. TRIAL REGISTRATION NUMBER: This trial was registered with and approved by the Chinese Clinical Trial Registry, with registration number ChiCTRcRRC-17011738, and was reviewed and approved by the Ethics Committee of Southwest Hospital.

2.
Respir Investig ; 59(3): 364-366, 2021 May.
Article in English | MEDLINE | ID: mdl-33602651

ABSTRACT

The fractional concentration of exhaled nitric oxide (FeNO) is recognized as a biomarker of type 2 inflammation in asthma, which is related to airway eosinophilia. We conducted a prospective observational study in a cohort of Japanese patients with chronic obstructive pulmonary disease (COPD) to evaluate the relationship between FeNO and clinical features and patient outcomes over a 3-year period. Participants were categorized into two groups based on FeNO levels (high and low), and the clinical features and outcomes were compared between the groups. Patients with high FeNO levels showed features of asthma and eosinophilic inflammation compared to those with low levels. However, high FeNO levels were not associated with worse outcomes (exacerbations, hospital admissions, all-cause and disease-specific mortality) compared to low levels. These results provide evidence that baseline FeNO is related to eosinophilic inflammation; however, is not a predictor of future exacerbations or prognosis in patients with stable COPD.


Subject(s)
Breath Tests/methods , Nitric Oxide/analysis , Pulmonary Disease, Chronic Obstructive/diagnosis , Aged , Aged, 80 and over , Biomarkers/analysis , Disease Progression , Eosinophils/pathology , Female , Humans , Inflammation , Male , Prognosis , Prospective Studies , Pulmonary Disease, Chronic Obstructive/pathology , Severity of Illness Index
3.
Neumol. pediátr. (En línea) ; 16(2): 62-68, 2021. ilus, tab
Article in Spanish | LILACS | ID: biblio-1293286

ABSTRACT

El asma es la enfermedad respiratoria crónica pediátrica más frecuente. En la mayoría de los niños se caracteriza por inflamación de la vía aérea de tipo eosinofílica alérgica. La fracción espirada de óxido nítrico (FENO) es un biomarcador de inflamación eosinofílica de vía aérea, su medición es no invasiva y fácil de realizar y ha sido evaluado en los últimos años para su aplicación clínica en el diagnóstico y tratamiento del asma en niños y adultos. Esta revisión abordará el origen anatómico y bioquímico del FENO, aspectos prácticos de su medición, valores de referencia y su aplicación clínica en el diagnóstico y tratamiento del asma pediátrico.


Asthma is the most common pediatric chronic disease characterized in most children by allergic eosinophilic airway inflammation. The exhaled fraction of nitric oxide (FENO) is a biomarker of eosinophilic airway inflammation, constituting a non-invasive and easy-to-perform test that has been evaluated in recent years for its clinical application in the diagnosis and treatment of asthma in children and adults. This review will address the anatomical and biochemical origin of FENO, practical aspects of its measurement, reference values and its clinical application in the diagnosis and treatment of pediatric asthma.


Subject(s)
Humans , Asthma/diagnosis , Nitric Oxide/analysis , Asthma/metabolism , Breath Tests , Biomarkers , Exhalation , Eosinophilia , Inflammation , Nitric Oxide/metabolism
4.
Eur J Appl Physiol ; 119(11-12): 2723-2731, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31676994

ABSTRACT

PURPOSE: Prolonged exposure to a high partial pressure of oxygen leads to inflammation of pulmonary tissue [pulmonary oxygen toxicity (POT)], which is associated with tracheobronchial irritation, retrosternal pain and coughing, and decreases in vital capacity (VC). The nitric oxide (NO) concentration in exhaled gas (FeNO) has been used as an indicator of POT, but the effect of SCUBA diving on FeNO has rarely been studied. The study presented here aimed to assess alterations to pulmonary function and FeNO following a 12-h dive using breathing apparatus with a relatively high partial pressure of oxygen. METHODS: Six healthy, male, non-smoking military SCUBA divers were recruited (age 31.8 ± 2.7 years, height 179 ± 0.09 cm, and body weight 84.6 ± 14 kg). Each diver completed a 12-h dive using a demand-controlled semi-closed-circuit rebreather. During the 12 h of immersion, divers were subjected to 672 oxygen toxicity units (OTU). A complete pulmonary function test (PFT) was completed the day before and immediately after immersion. FeNO was measured using a Nobreath™ Quark (COSMED™, Rome, Italy), three times for each diver. The first datapoint was collected before the dive to establish the "basal state", a second was collected immediately after divers emerged from the water, and the final measurement was taken 24 h after the dive. RESULT: Despite prolonged inhalation of a hyperoxic hyperbaric gas mixture, no clinical pulmonary symptoms were observed, and no major changes in pulmonary function were detected. However, a major decrease in FeNO values was observed immediately after emersion [0-12 ppb (median, 3.8 ppb)], with a return to baseline [2-60 ppb (median, 26 ppb) 24 h later (3-73 ppb (median, 24.7 ppb)]. CONCLUSION: These results suggest that if the OTU remain below the recommended limit values, but does alter FeNO, this type of dive does not persistently impair lung function.


Subject(s)
Diving/adverse effects , Lung/drug effects , Nitrogen/adverse effects , Oxygen/adverse effects , Administration, Inhalation , Adult , Exhalation/drug effects , Humans , Hyperoxia/metabolism , Male , Nitric Oxide/metabolism , Oxygen/metabolism , Partial Pressure , Respiratory Function Tests/methods , Vital Capacity/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL